Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Prostate Cancer · Hot Flush

Astellas Pharma

Astellas Pharma GmbH

Astellas Pharma trial registry — 22 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, JP HQ
12,378 Employees
EMA registrant Type
Company details
Status
Public
HQ
2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, JP
Employees
12,378
Programs
22
Drugs
52
Patents
25
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Trials

Astellas Pharma clinical trials

Registry index of 22 ClinicalTrials.gov studies linked to Astellas Pharma programs — each row shows trial ID, program name, phase, status, and indication.

Astellas Pharma trial registry — 22 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for Astellas Pharma.

  1. 8951-CL-0302 — Phase 3

    Clinical update

  2. 8951-CL-0301 — Phase 3

    Clinical update

  3. 2693-CL-1303 — Phase 3

    Clinical update

  4. 2215-CL-5201 — Phase 1

    Clinical update

  5. 2215-CL-0201 — Phase 3

    Clinical update

  6. 9785-CL-0123 — Phase 2

    Clinical update

  7. 8951-CL-0103 — Phase 2

    Clinical update

  8. 2215-CL-0603 — Phase 2

    Clinical update

Trial registry

22 studies
  9. 2024-511648-16-00

    8951-CL-0302

    Phase 3 active small_molecule

    Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

    CTIS ↗
  11. 2024-512469-15-00

    2215-CL-0603

    Phase 2 active small_molecule

    FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

    CTIS ↗

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.